Systolic heart failure
Drug research and approvals for systolic heart failure: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 48 studies of systolic heart failure are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 48
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Biomarkers for Left Ventricular Reverse Remodeling in Heart Failure (REVERT-HF)NCT07701876 · Not reported · Ruijin Hospital Luwan Branch · starts Nov 1, 2025
- AI ECG Algorithm for Detecting LV Systolic DysfunctionNCT07636759 · Not reported · Ajou University School of Medicine · starts Jan 1, 2026
- A Study of LY3971297 in Participants With Heart FailureNCT07547540 · Phase 1 · Eli Lilly and Company · starts Aug 11, 2026
- Selenium Intervention Registry Randomized Trial in Heart FailureNCT07543562 · Phase 3 · Skane University Hospital · starts Apr 1, 2026
- Advancing Clinical Heart Failure Outcomes Leveraging Defibrillation Lead Implant System for Left Bundle Branch Area…NCT07526896 · Not applicable · Medtronic Cardiac Rhythm and Heart Failure · starts Oct 13, 2026
- RHYthm and Myocardial Function Relationship Evaluation in Heart DiseasesNCT07491237 · Not reported · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · starts Jun 23, 2026
- Infusing Needed Iron to Target Insufficiency in Adults Treated for Evidence of Heart FailureNCT07467668 · Not applicable · Kaiser Permanente · starts Apr 20, 2026
- Echocardiography-Based Predictors of Outcomes in Hospitalized Patients With Decompensated Heart Failure (ECHO-DECOMP)NCT07439159 · Not reported · Istanbul University - Cerrahpasa · starts Mar 3, 2024
- Comparing Three Types of Specialist Pacemakers to Improve Heart Function and Reduce Rhythm Problems in Heart FailureNCT07430553 · Not applicable · Imperial College London · starts Nov 12, 2025
Approved 1
- DapagliflozinSodium/glucose cotransporter 2 inhibitor
Phase 3 2
- Human neuregulin-1 recombinant (177-237)
- UdenafilPhosphodiesterase 5A inhibitor
Phase 2 6
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- ProbenecidSolute carrier family 22 member 6 inhibitor
- RifaximinBacterial DNA-directed RNA polymerase inhibitor
- IvabradinePotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker
- Niacin
- Nitric acid
Phase 1 or earlier 5
- Albumin humanBilirubin sequestering agent
- DapansutrileNACHT, LRR and PYD domains-containing protein 3 inhibitor
- Nicotinamide riboside
- Lenrispodun
- Nelutroctiv
How its trials ended
198 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 46 whose ending is known, 35% met their primary endpoint, 7% missed it and 59% stopped early.
- Completed, result not reported6533%
- Ongoing4523%
- Status unknown4221%
- Met its primary endpoint168%
- Stopped: other or unclear168%
- Stopped: enrollment or feasibility53%
- Stopped: sponsor or business decision42%
- Missed its primary endpoint32%
- Stopped: lack of efficacy11%
- Stopped: funding11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA